Lung Cancer News and Research RSS Feed - Lung Cancer News and Research Twitter

Lung cancer is the world's most common cancer and kills more people than any other cancer. In 2008, approximately 1.52 million new cases of lung cancer were diagnosed worldwide, with 1.31 million people dying from the disease.(14) In the United States, an estimated 161,840 deaths, accounting for 29 percent of all cancer deaths, occurred in 2008, according to the American Cancer Society (ACS).
Research brief provides clinical validation of LOXO-101 Phase 1 trial for treatment of TRK fusion cancer

Research brief provides clinical validation of LOXO-101 Phase 1 trial for treatment of TRK fusion cancer

The University of Colorado Cancer Center and Loxo Oncology, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of targeted cancer therapies, today announced the publication of a research brief in the online edition of the journal Cancer Discovery, describing the first patient with a tropomyosin receptor kinase fusion cancer enrolled in the Phase 1 dose escalation trial of LOXO-101, the only selective TRK inhibitor in clinical development. [More]
VolitionRx selects Global Specimen Solutions to support U.S. market entry of NuQ colorectal cancer tests

VolitionRx selects Global Specimen Solutions to support U.S. market entry of NuQ colorectal cancer tests

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that it has engaged the services of a specialty specimen management clinical research organization, Global Specimen Solutions, Inc., to support initial U.S. market entry of its NuQ colorectal cancer tests. [More]
Research brief describes enrollment of first patient with TRK fusion cancer in LOXO-101 Phase 1 trial

Research brief describes enrollment of first patient with TRK fusion cancer in LOXO-101 Phase 1 trial

The University of Colorado Cancer Center and Loxo Oncology, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of targeted cancer therapies, today announced the publication of a research brief in the online edition of the journal Cancer Discovery, describing the first patient with a tropomyosin receptor kinase (TRK) fusion cancer enrolled in the Phase 1 dose escalation trial of LOXO-101, the only selective TRK inhibitor in clinical development. [More]
ALCF to honor Fred R. Hirsch with 2015 Addario Lectureship Award for lung cancer research

ALCF to honor Fred R. Hirsch with 2015 Addario Lectureship Award for lung cancer research

The Bonnie J. Addario Lung Cancer Foundation will honor Fred R. Hirsch, M.D., Ph.D., with the 2015 Addario Lectureship Award for his continued leadership and expertise in lung cancer treatment and research. Dr. Hirsch, CEO of the International Association for the Study of Lung Cancer, will receive the award at the 16th International Lung Cancer Congress held on July 30 – August 1 in Huntington Beach, California. [More]
Smoke-free policy can improve living environment for apartment dwellers

Smoke-free policy can improve living environment for apartment dwellers

Adopting a smoke-free policy can improve the living environment for apartment dwellers while reducing maintenance costs, according to a survey of multiunit housing owners and operators. [More]
Phase 3 SUMIT study: Selumetinib fails to meet primary endpoint in patients with metastatic uveal melanoma

Phase 3 SUMIT study: Selumetinib fails to meet primary endpoint in patients with metastatic uveal melanoma

AstraZeneca today announced that the Phase 3 SUMIT study of selumetinib in combination with dacarbazine for the treatment of patients with metastatic uveal melanoma did not meet its primary endpoint of progression free survival. This combination therapy showed an adverse event profile generally consistent with current knowledge of the safety profiles of dacarbazine and selumetinib. [More]
UCLA's Jonsson Comprehensive Cancer Center named among top 10 cancer centers in nation

UCLA's Jonsson Comprehensive Cancer Center named among top 10 cancer centers in nation

UCLA's Jonsson Comprehensive Cancer Center is ranked among the top 10 cancer centers in the nation, according to a U.S. News & World Report survey of board-certified physicians from across the country. The survey reviewed patient outcomes, the cancer center's reputation among physicians, mortality rates and other care-related factors. [More]
Research: 'Pill on a string' could help detect early signs of oesophageal cancer

Research: 'Pill on a string' could help detect early signs of oesophageal cancer

A 'pill on a string' developed by researchers at the University of Cambridge could help doctors detect oesophageal cancer - cancer of the gullet - at an early stage, helping them overcome the problem of wide variation between biopsies, suggests research published today in the journal Nature Genetics. [More]
Increased radiation dose offers survival benefit for men with medium- and high-risk prostate cancer

Increased radiation dose offers survival benefit for men with medium- and high-risk prostate cancer

Increased radiation dose is associated with higher survival rates in men with medium- and high-risk prostate cancer, but not men with low-risk prostate cancer, according to a new study from Penn Medicine published this week in JAMA Oncology. Already-high survival rates for men with low-risk prostate cancer were unaffected by higher radiation dosages compared to lower radiation dosages. [More]
Medtronic launches GenCut Core Biopsy System for minimally invasive use with the superDimension navigation system for lung tissue biopsies

Medtronic launches GenCut Core Biopsy System for minimally invasive use with the superDimension navigation system for lung tissue biopsies

Medtronic now offers the GenCut(TM) core biopsy system, a unique lung tissue biopsy tool for use with the superDimension(TM) navigation system. The superDimension(TM) system enables a minimally invasive approach to accessing difficult-to-reach areas of the lung, which can aid in the diagnosis of lung cancer. [More]
Big data project: CWRU wins federal grant to develop platform for collection, analysis of clinical data

Big data project: CWRU wins federal grant to develop platform for collection, analysis of clinical data

Case Western Reserve University is one of three institutions nationwide to win federal 'big data' grants focused on developing ways to ensure the integrity and comparability of the reams of information the U.S. health care system collects every day. If successful, the work could create enormous new opportunities to glean insights that help physicians cure or even prevent illness and disease. [More]
Clinical data on TomoTherapy System presented at AAPM 2015

Clinical data on TomoTherapy System presented at AAPM 2015

Accuray Incorporated announced today that studies on the clinical use of the TomoTherapy System continue to demonstrate its mainstream use and the benefits of its gold-standard treatment planning and delivery capabilities. More than 30 studies were presented during poster or oral sessions at the 57th Annual Meeting of the American Association of Physicists in Medicine held in Anaheim, California July 12 – July 16, 2015. [More]
Tobacco cessation service provides survival benefit for lung cancer patients who quit smoking

Tobacco cessation service provides survival benefit for lung cancer patients who quit smoking

Tobacco cessation provided significant survival benefit for lung cancer patients who quit smoking shortly before or after diagnosis, despite the severity of the disease. Results of the Roswell Park Cancer Institute study were published in the Journal of Thoracic Oncology. [More]
QIAGEN's therascreen EGFR RGQ PCR Kit to guide use of IRESSA for in NSCLC treatment

QIAGEN's therascreen EGFR RGQ PCR Kit to guide use of IRESSA for in NSCLC treatment

QIAGEN N.V. today received U.S. marketing (PMA) approval of its therascreen EGFR RGQ PCR Kit (therascreen EGFR test) as a companion diagnostic to guide the use of AstraZeneca's IRESSA (gefitinib) in the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC). [More]
OncoGenex's custirsen Phase 3 ENSPIRIT trial for treatment of NSCLC patients continues as planned

OncoGenex's custirsen Phase 3 ENSPIRIT trial for treatment of NSCLC patients continues as planned

OncoGenex Pharmaceuticals, Inc. announced today that its Phase 3 ENSPIRIT trial evaluating custirsen in the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) is continuing as planned per the recommendation of an Independent Data Monitoring Committee (IDMC). This decision was based upon completion of the second and final planned interim futility analysis. [More]
New screening program using CT scan technology can help better detect lung cancer in smokers

New screening program using CT scan technology can help better detect lung cancer in smokers

Long-time smokers and past smokers now have a more accurate way of detecting whether or not they have lung cancer thanks to a comprehensive lung cancer screening program that uses CT scan technology at Intermountain Medical Center in Salt Lake City. [More]
Ludwig, CRI launch clinical trials to evaluate immunotherapies for treatment of GBM and solid tumors

Ludwig, CRI launch clinical trials to evaluate immunotherapies for treatment of GBM and solid tumors

Ludwig Cancer Research and the Cancer Research Institute have launched clinical trials evaluating an immunotherapy for the treatment of the brain cancer glioblastoma multiforme (GBM), and a combination of immunotherapies for a variety of solid tumors. [More]
LUX-Lung 8 supports afatinib in squamous NSCLC

LUX-Lung 8 supports afatinib in squamous NSCLC

Compared with erlotinib, treatment with afatinib leads to outcomes in previously treated patients with advanced squamous non-small-cell lung cancer, suggest the results of a head-to-head trial. [More]
New WHO report focuses on raising taxes on tobacco, stamping out tobacco epidemic

New WHO report focuses on raising taxes on tobacco, stamping out tobacco epidemic

Too few governments levy appropriate levels of tax on cigarettes and other tobacco products. They therefore miss out on a proven, low-cost measure to curb demand for tobacco, save lives and generate funds for stronger health services, according to the "WHO Report on the global tobacco epidemic 2015". [More]
Boehringer Ingelheim LUX-Lung 8 trial reveals afatinib better than erlotinib to treat SCC of the lung

Boehringer Ingelheim LUX-Lung 8 trial reveals afatinib better than erlotinib to treat SCC of the lung

Boehringer Ingelheim today announced The Lancet Oncology has published results from the LUX-Lung 8 trial. LUX-Lung 8 is the largest, prospective Phase III head-to-head trial directly comparing two EGFR-directed treatments. [More]
Advertisement